Ectopic Bone Formation by Mesenchymal Stem Cells Derived from Human Term Placenta and the Decidua

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Biomaterials Science

Background:

• Mesenchymal stem cells (MSCs) are crucial for bone tissue repair.
• Human term placenta yields fetal-derived MSCs (chorionic-derived MSCs, CMSCs) and maternal-derived MSCs (decidual-derived MSCs, DMSCs).

Purpose of the Study:

• To evaluate the bone-forming potential of CMSCs and DMSCs for regenerative medicine applications.
• To confirm if placental MSCs meet the International Society of Cellular Therapy criteria for MSCs.

Main Methods:

• Isolated CMSCs and DMSCs from human term placenta.
• Characterized cells based on adherence to plastic, surface marker expression (CD73, CD105, CD90, CD146, CD44, CD166, CD45, CD19, HLA-DR), and multi-lineage differentiation potential.
• Assessed in vivo bone formation via subcutaneous implantation of BrdU-labeled cells with hydroxyapatite/tricalcium phosphate particles in SCID mice.
• Performed histological analysis for bone markers (OPN, OCN, BGN, BSP) and vasculature marker (α-SMA).

Main Results:

• Both CMSCs and DMSCs fulfilled the International Society of Cellular Therapy criteria for MSCs.
• In vivo studies demonstrated ectopic bone formation by both CMSCs and DMSCs at 8 weeks post-transplantation.
• Histological analysis confirmed the expression of key bone formation and vascularization markers.

Conclusions:

• CMSCs and DMSCs exhibit robust osteogenic capacity.
• These placental-derived MSCs are promising cellular candidates for bone tissue engineering and regenerative therapies.